Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

CORT Cover Image

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ: CORT) and its peers.

The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial investments in research and development to create innovative, patent-protected drugs. Successful products can generate significant revenue streams over their patent life, and the larger a roster of drugs, the stronger a moat a company enjoys. However, the business model is inherently risky, with high failure rates during clinical trials, lengthy regulatory approval processes, and intense competition from generic and biosimilar manufacturers once patents expire. These challenges, combined with scrutiny over drug pricing, create a complex operating environment. Looking ahead, the industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds include heightened regulatory scrutiny, pricing pressures from governments and insurers, and the looming patent cliffs for key blockbuster drugs. Patent cliffs bring about competition from generics, forcing branded pharmaceutical companies back to the drawing board to find the next big thing.

The 11 branded pharmaceuticals stocks we track reported a mixed Q4. As a group, revenues beat analysts’ consensus estimates by 1.3%.

In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results.

Corcept (NASDAQ: CORT)

Founded in 1998, Corcept Therapeutics (NASDAQ: CORT) develops and commercializes medications for the treatment of severe metabolic, oncologic, and psychiatric disorders associated with cortisol dysregulation.

Corcept reported revenues of $181.9 million, up 34.3% year on year. This print fell short of analysts’ expectations by 8.5%. Overall, it was a slower quarter for the company with a significant miss of analysts’ EPS estimates.

Corcept Total Revenue

Corcept achieved the highest full-year guidance raise but had the weakest performance against analyst estimates of the whole group. Still, the market seems discontent with the results. The stock is down 14.5% since reporting and currently trades at $61.46.

Read our full report on Corcept here, it’s free.

Best Q4: Supernus Pharmaceuticals (NASDAQ: SUPN)

Founded in 2005, Supernus Pharmaceuticals (NASDAQ: SUPN) develops and commercializes treatments for central nervous system (CNS) disorders, focusing on epilepsy, ADHD, and Parkinson’s disease.

Supernus Pharmaceuticals reported revenues of $174.2 million, up 6% year on year, outperforming analysts’ expectations by 12.2%. The business had a very strong quarter with a solid beat of analysts’ EPS estimates and full-year operating income guidance topping analysts’ expectations.

Supernus Pharmaceuticals Total Revenue

Supernus Pharmaceuticals pulled off the biggest analyst estimates beat among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 14.5% since reporting. It currently trades at $28.08.

Is now the time to buy Supernus Pharmaceuticals? Access our full analysis of the earnings results here, it’s free.

Weakest Q4: Zoetis (NYSE: ZTS)

Originally a subsidiary of Pfizer, Zoetis (NYSE: ZTS) is an animal health company that develops and distributes medicines, vaccines, and diagnostic products for livestock and pets.

Zoetis reported revenues of $2.32 billion, up 4.7% year on year, in line with analysts’ expectations. It was a softer quarter as it posted a significant miss of analysts’ full-year EPS guidance estimates.

As expected, the stock is down 2.8% since the results and currently trades at $169.01.

Read our full analysis of Zoetis’s results here.

Royalty Pharma (NASDAQ: RPRX)

Founded in 1996, Royalty Pharma (NASDAQ: RPRX) acquires pharmaceutical royalties and funds late-stage clinical trials, offering a unique revenue model centered on financing innovative drug development.

Royalty Pharma reported revenues of $594 million, flat year on year. This number lagged analysts' expectations by 1.9%. All in all, it was a slower quarter for the company.

The stock is up 6.7% since reporting and currently trades at $33.87.

Read our full, actionable report on Royalty Pharma here, it’s free.

Organon (NYSE: OGN)

Founded in 2020, Organon (NYSE: OGN) offers healthcare products focused on women's health.

Organon reported revenues of $1.59 billion, flat year on year. This print beat analysts’ expectations by 0.9%. However, it was a slower quarter as it recorded full-year revenue guidance missing analysts’ expectations.

Organon had the slowest revenue growth among its peers. The stock is down 1.8% since reporting and currently trades at $14.43.

Read our full, actionable report on Organon here, it’s free.


Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

Join Paid Stock Investor Research

Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.